Exelixis succeeds on a do-over
In 2014, Exelixis tried to develop a drug for prostate cancer, but the clinical trial ended in failure and nearly shut down the company. A second attempt has delivered better, tumor-shrinking results, according to data released last night, while still leaving some important questions unanswered.
A combination regimen for prostate cancer consisting of Exelixis’ targeted cancer drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq could be filed with the Food and Drug Administration in 2021; if approved, the therapy would help Exelixis achieve its aggressive goal of more than quadrupling Cabometyx sales by the end of 2025.
But as Adam Feuerstein also reports, not all prostate cancer doctors believe Exelixis’ new combination therapy will work better than old-fashioned chemotherapy. And competitors, including Merck and Bristol-Myers Squibb, are lurking close behind.
Read more.
A combination regimen for prostate cancer consisting of Exelixis’ targeted cancer drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq could be filed with the Food and Drug Administration in 2021; if approved, the therapy would help Exelixis achieve its aggressive goal of more than quadrupling Cabometyx sales by the end of 2025.
But as Adam Feuerstein also reports, not all prostate cancer doctors believe Exelixis’ new combination therapy will work better than old-fashioned chemotherapy. And competitors, including Merck and Bristol-Myers Squibb, are lurking close behind.
Read more.
.png)
No hay comentarios:
Publicar un comentario